Skip to main content
Swing Capital

Global Health Ltd

NSE: MEDANTA BSE: 543654

Global Health Limited is one of the largest private multi-specialty tertiary care providers operating in the North and East regions of India. The company has key specialties in cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology.[1]

₹1,238
52W: ₹955 — ₹1456
PE 67.1 · Book ₹149 · +731% vs book
Market Cap₹33,295 Cr
Stock P/E67.1Price to Earnings
ROCE17.1%Return on Capital
ROE13.2%Return on Equity
Div. Yield0.04%Face Value ₹2

Strengths

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Company has delivered good profit growth of 54.3% CAGR over last 5 years

Weaknesses

  • −Stock is trading at 8.14 times its book value

Shareholding Pattern

Promoters33.01%
FIIs10.15%
DIIs14.76%
Public42.01%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters33.04%33.04%33.03%▼0.033.03%33.01%▼0.033.01%33.01%33.01%
FIIs12.94%12.21%▼0.712.48%▲0.311.76%▼0.711.54%▼0.211.41%▼0.110.54%▼0.910.15%▼0.4
DIIs10.57%11.11%▲0.510.51%▼0.611.93%▲1.412.2%▲0.312.97%▲0.813.99%▲1.014.76%▲0.8
Public43.44%43.64%▲0.243.98%▲0.343.28%▼0.743.19%▼0.142.56%▼0.642.41%▼0.242.01%▼0.4

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales565724611665812803882926940961
Expenses439560479514611608688734766767
Operating Profit126164132150202195195193174193
OPM %22%23%22%23%25%24%22%21%19%20%
Net Profit87109961041319315214080124
EPS ₹3.254.083.593.894.893.485.655.222.974.62

AI Insights

Revenue Trend

Mar 2026 revenue at ₹3,709Cr, up 15.8% YoY. OPM at 20%.

Debt Position

Borrowings at ₹233Cr. Debt-to-equity ratio: 0.06x. Healthy balance sheet.

Capex Cycle

CWIP at ₹120Cr (4% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 14.76% (+3.97pp change). FIIs: 10.15% (-0.43pp change). Promoters hold 33.01%.

Margin & Efficiency

ROCE improving from 0% (Mar 2017) to 17% (Mar 2026). Working capital days: -4.

Valuation

PE 67.1x with 17.1% ROCE. Price is 731% above book value of ₹149. Dividend yield: 0.04%.

Recent Announcements